

David Wood, MD, FAACT

Please share your current and past involvement in AACT, AACT-related activities and/or ABAT.

- My first NACCT was in 2006, attending every year since (apart from 2020/21 due to COVID)
- Invited Lectures: 3 main congress, 2 AACT pre-congress and 1 ACMT pre-congress
- Abstracts: 62 posters (32 as 1st and 13 as senior author), 6 orals (1 as senior author)
- Member of the AACT Scientific Review Committee (2014 to 2018)
- Member of the AACT/EAPCCT/APAMT collaborative activated charcoal (2016 onwards) and paracetamol (2021 onwards) projects
- Member of Extracorporeal Treatments in Poisoning 2 (EXTRIP2) (2018 onwards)
- Lead on the methotrexate and ethylene glycol guidelines and recommendations
- Member of the AACT Antidotes Collective (2024 onwards)
- NAACT abstract reviewer (2025 onwards)
- Member of AACT research award committee (2025 onwards)
- Member of AACT fellowship committee (2025 onwards)

Please note any previous leadership and/or board experience(s) in other associations and/or institutions.

In addition to the summary of clinical and non-clinical leadership roles outlined in my attached CV, particular leadership and board experience to highlight include:

- British Pharmacological Society:
- Clinical Section Trustee on Council (2013-15)
- Finance & Risk (2010-13) and Members and Awards (2010-16) committees
- Journal of Medical Toxicology: Editorial Board (2011-23); Senior Editor (2023 onwards)
- European Association of Poisons Centres and Clinical Toxicologists
- EAPCCT Scientific Committee: Member May 2020 to May 2024
- EAPCCT Scientific Committee: Chair Elect from January 2025, taking over as Chair in May 2026
- UK Royal College of Physicians: representative to the UK Royal College of Pathologists Specialist Advisory Committee (SAC) on Toxicology (2016 onwards)
- Positive East, a UK HIV charity: Board of Trustees member (2022 onwards)
- UK Advisory Council on the Misuse of Drugs (ACMD):
- Co-opted expert 2007 to 2020
- Member of the ACMD Council since August 2020

Please share your vision and goals as a member of the Board of Trustees.

Throughout my training in medical toxicology and subsequent appointment as a consultant (attending) in 2007, I have been an avid supporter of the AACT and the NACCT annual congress. Through my AACT engagement, I have formed both personal and professional relationships with many individuals within the AACT. Additionally, on behalf of the AACT, and its sister organisations the EAPCCT and APAMT, I have become involved in a number AACT related US and international clinical toxicology projects. I have taken also taken on a variety of additional roles on behalf of AACT. The value of international collaboration is vital not only to the development of the field of Clinical Toxicology, but to dealing with some of the challenges such as controversies in management and shortages of treatments/antidotes.

In applying to be a Trustee of the AACT Board of Trustees, my vision is to "improve and increase the international participation in the activities of the AACT" and my goals include:

• Enhancing the relationships between the AACT and other international toxicological (such as MENATOX) and societies with interests allied to toxicology (such as emergency medicine);

- Increasing the involvement and participation of international members in the AACT; and
- · Increasing the international reach and context of AACT related activities and outputs.
- Promoting membership of the AACT to international toxicologists